Cagrilintide vs GLP-2/Tirz
The amylin arm against the dual incretin arm — the two halves of the combination research that has defined this field since 2021.
How they actually differ
GLP-2/Tirz is a dual agonist at GIP and GLP-1 receptors; cagrilintide is an amylin analogue acting at an entirely separate receptor family. The published head-to-head evidence is indirect and worth stating carefully: in REDEFINE 4 (2026), cagrilintide co-administered with semaglutide did not meet non-inferiority against tirzepatide 15 mg at 84 weeks. Handling is similar in kind — both are long, acylated, foam-prone syntheses — but cagrilintide carries a Cys2–Cys7 disulfide that GLP-2/Tirz does not, which makes disulfide pairing a genuine identity question on its certificate of analysis rather than a formality.
Cagrilintide — origin
Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.
GLP-2/Tirz — origin
GLP-2/Tirz is built on a GIP-based backbone rather than a GLP-1 one — an important and often-missed design detail. It was engineered from the GIP sequence and modified to acquire GLP-1 receptor activity, with a C20 fatty diacid attached via a linker for albumin binding. The term "twincretin" describes the dual incretin activity.
Cagrilintide research themes
Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.
A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.
The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.
The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.
GLP-2/Tirz research themes
Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.
Core metabolic research endpoints for the incretin class.
A well-characterised GLP-1 pathway effect studied in metabolic models.
Whether GIP agonism or antagonism is the productive direction remains an active research debate.
Cagrilintide handling
- Never shake. Swirl gently and allow the cake to dissolve in its own time.
- Do not freeze reconstituted solution.
- Add diluent down the vial wall rather than directly onto the cake.
- Treat visible particulate or a settling precipitate as a rejected vial — for an amylin analogue this is the observable end of the fibrillation pathway, not a cosmetic issue.
GLP-2/Tirz handling
- Swirl, never shake or vortex.
- Add diluent down the vial wall and give the cake time — several minutes of slow dissolution is normal, not a defect.
- Store upright and refrigerated; do not freeze once reconstituted.
Both third-party tested
Every Popular Peptides batch of Cagrilintide and GLP-2/Tirz is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
Cagrilintide reference
Related comparisons
Cagrilintide and GLP-2/Tirz are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.